Obesity Clinical Trials in Mesquite, Texas
5 studies are recruiting for obesity in Mesquite, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…
- Stage
- Phase 2
- Ages
- 18 to 75
- Site
- Southern Endocrinology Associates /ID# 282558, Mesquite, Texas
- Locations
- 64 in total
- Run by
- AbbVie
-
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Southern Endocrinology Associates, Mesquite, Texas
- Locations
- 143 in total
- Run by
- Eli Lilly and Company
-
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).
- Stage
- Phase 3
- Ages
- 18 to 99
- Site
- Southern Endocrinology Associates PA, Mesquite, Texas
- Locations
- 92 in total
- Run by
- Amgen
-
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- AURORA-2 Clinical Site, Mesquite, Texas
- Locations
- 135 in total
- Run by
- Ascletis Pharma (China) Co., Limited
-
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight wit…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- AURORA-1 Clinical Site, Mesquite, Texas
- Locations
- 122 in total
- Run by
- Ascletis Pharma (China) Co., Limited
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.